Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, director, Neurosurgical Oncology; professor, Department of Neurological Surgery, the Brain and Spine Tumor Center, The Ohio State University Wexner Medical Center, discusses 

blinded early-safety data from a phase 2b trial (NCT04485949)

 investigating the autologous cell immunotherapy IGV-001 in patients with newly diagnosed glioblastoma.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Brain Cancer

 Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Society for Neuro-Oncology Annual Meeting

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.